- Conditions
- Aneurysm
- Interventions
- GORE CTAG Device
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,005
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- La Jolla, California • Shreveport, Louisiana • Detroit, Michigan
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Interventions
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- RP101, Gemcitabine (1000 mg/m2)
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Beverly Hills, California • San Francisco, California + 13 more
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Fruquintinib Combined With Chemotherapy
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more
- Conditions
- Cancer, Relapsed Cancer, Refractory Cancer
- Interventions
- Cellworks Report
- Other
- Lead sponsor
- Cellworks Group Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Pancreas Cancer
- Interventions
- Pembrolizumab, Azacitidine
- Drug
- Lead sponsor
- Susan E. Bates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer, NSCLC
- Interventions
- Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 851 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Burbank, California • San Diego, California + 17 more
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
- Interventions
- Nivolumab, Sorafenib
- Biological · Drug
- Lead sponsor
- Robin Kate Kelley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • San Francisco, California
- Conditions
- Colorectal Cancer
- Interventions
- Tivozanib, Bevacizumab, mFOLFOX6
- Drug
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 27
- States / cities
- Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 14 more
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Tislelizumab, Sorafenib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 684 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Orange, California + 6 more
- Conditions
- Liver Cancer
- Interventions
- bevacizumab, erlotinib hydrochloride, sorafenib tosylate
- Biological · Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 116 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • New York, New York + 3 more
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Niraparib, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 21
- States / cities
- Fullerton, California • Los Angeles, California • Lone Tree, Colorado + 18 more
- Conditions
- Lung Cancer
- Interventions
- Nivolumab, Ipilimumab, Placebo
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 28
- States / cities
- Sacramento, California • New Haven, Connecticut • Fort Myers, Florida + 23 more
- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
- Conditions
- HIV
- Interventions
- Atazanavir, Darunavir, Ritonavir, Optimized NRTI backbone
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Epcoritamab, Lenalidomide
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 75 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Waukesha, Wisconsin
- Conditions
- Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- ABT-869, Placebo for ABT-869, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Peoria, Arizona • Miami, Florida + 9 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Itacitinib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 45
- States / cities
- Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more
- Conditions
- Colorectal Cancer
- Interventions
- capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 76
- States / cities
- PARK Springs, Arizona • Sedona, Arizona • Tucson, Arizona + 68 more
- Conditions
- Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Olaparib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 5 more